| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 1 | T | 1 CC-486 + R-miniCHOP | 422 | 69 | 9 | 0 | 0 | 0 | 0 | 05/25/2021 | 199 | 70 |
| 2 R-miniCHOP | 67 | 9 | 0 | 0 | 0 | 0 | ||||||||
| 136 | 18 | 0 | 0 | 0 | 0 | |||||||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 169 | 86 | 40 | 22 | 12 | 3 | 06/12/2023 | 98 | 39 | |
| 169 | 86 | 40 | 22 | 12 | 3 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 9 | 5 | 2 | 1 | 0 | 0 | 06/12/2023 | |||||
| 2 Polatuzumab | 8 | 5 | 1 | 0 | 0 | 0 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 8 | 4 | 1 | 0 | 0 | 0 | ||||||||
| 4 Observation | 8 | 4 | 2 | 1 | 0 | 0 | ||||||||
| 33 | 18 | 6 | 2 | 0 | 0 | |||||||||
| 3 | Y | 5 Mosunetuzumab + Polatuzumab | 4 | 3 | 1 | 1 | 1 | 0 | 06/12/2023 | |||||
| 4 | 3 | 1 | 1 | 1 | 0 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | T | 1 Tazemetostat (Arm 1) Dose Level 1 | 241 | 7 | 0 | 0 | 0 | 0 | 0 | 09/26/2023 | 136 | 42 | |
| 10 Tazemetostat (Arm 1) Dose Level 1 | 6 | 6 | 6 | 6 | 2 | 0 | ||||||||
| 13 Zanubrutinib (Arm 3) Dose Level 2 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||||
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 34 | 8 | 7 | 7 | 3 | 0 | |||||||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | 1 | Y | 1 Rituximab | 600 | 97 | 97 | 59 | 27 | 4 | 1 | 10/23/2024 | 257 | 89 | |
| 2 Mosunetuzumab | 99 | 98 | 61 | 30 | 8 | 3 | ||||||||
| 196 | 195 | 120 | 57 | 12 | 4 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 19 | 8 | 4 | 1 | 0 | 0 | 10/14/2023 | 186 | 79 | |
| 19 | 8 | 4 | 1 | 0 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 24 | 12 | 7 | 5 | 2 | 1 | 01/03/2024 | 207 | 74 | ||
| 24 | 12 | 7 | 5 | 2 | 1 | |||||||||
| 2 | E | Total Registrations | 12 | 9 | 3 | 2 | 1 | 0 | 01/03/2024 | |||||
| 12 | 9 | 3 | 2 | 1 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 72 | 44 | 23 | 8 | 4 | 1 | 08/15/2023 | 274 | 126 | ||
| 72 | 44 | 23 | 8 | 4 | 1 | |||||||||
| 2 | E | Total Registrations | 62 | 41 | 26 | 12 | 1 | 0 | 08/15/2023 | |||||
| 62 | 41 | 26 | 12 | 1 | 0 | |||||||||
| No | EA4232-Lymph, Peri T Cell, Auto Stem | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 09/15/2025 | 25 | 3 | |
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| OPEN | Study | Date Closed |
Reg. | Arm | Total Regs |
Regs Last 30 Days |
Regs Last 7 Days |
|---|---|---|---|---|---|---|---|
| T | S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 20-Oct-25 | 1 | 1 Tazemetostat (Arm 1) Dose Level 1 | 7 | 0 | 0 |
| 10 Tazemetostat (Arm 1) Dose Level 1 | 6 | 2 | 0 | ||||
| 13 Zanubrutinib (Arm 3) Dose Level 2 | 1 | 1 | 0 | ||||
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | ||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 0 | 0 |